ALT Form 4: Director Diane Jorkasky Receives 48,800 Options, Vesting 12 Months

Rhea-AI Filing Summary

Diane Jorkasky, a director of Altimmune, Inc. (ALT), received a grant of stock options on 09/25/2025. The Form 4 shows an award of 48,800 stock options with an exercise price of $3.92 per share and an expiration date of 09/25/2035. The options were reported as acquired and are held directly by the reporting person. The shares underlying the option vest in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. The filing was signed by Gregory Weaver as Attorney-in-Fact on 09/29/2025.

Positive

• Director received a clear equity grant — 48,800 options disclosed, demonstrating alignment with shareholder interests through equity compensation.
• Transparent vesting schedule — shares vest in substantially equal monthly installments over 12 months, explicitly stated in the filing.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A director received a time‑based option grant that vests over one year, aligning compensation with continued service.

The Form 4 documents a direct grant of 48,800 options to a board director at a $3.92 exercise price, exercisable through 09/25/2035. The one‑year monthly vesting schedule ties the director's economic interest to continued service rather than immediate liquidity. From a governance perspective, such short‑term time‑based vesting is common for retention and alignment, and the filing properly discloses the details without additional caveats.

Securities Analyst

TL;DR: The filing reports a standard director option grant; it is a routine disclosure with limited immediate market impact.

The transaction is an acquisition (A) of 48,800 options at $3.92, with underlying common stock also shown as 48,800 shares beneficially owned post‑transaction. The long expiration (2035) and short vesting window (12 months) indicate standard incentive structure. The Form 4 provides clear, specific data on quantity, price, vesting cadence, and exercisability date, enabling straightforward modeling of potential dilution if exercised, but does not itself contain financial results or broader corporate developments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jorkasky Diane

(Last) (First) (Middle)

C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)	$3.92	09/25/2025		A		48,800		(1)	09/25/2035	Common Stock, par value $0.0001	48,800	$0.00	48,800	D

Explanation of Responses:

1. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gregory Weaver, as Attorney-in-Fact	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Diane Jorkasky report on Form 4 for Altimmune (ALT)?

She reported an acquisition of 48,800 stock options on 09/25/2025 with an exercise price of $3.92 and expiration 09/25/2035.

How do the options granted to the director vest?

The options vest in substantially equal monthly installments over the 12 months

Are the options reported as direct or indirect ownership?

The filing reports the ownership form as Direct (D)

When was the Form 4 signed and by whom?

The form was signed by Gregory Weaver, as Attorney‑in‑Fact, on 09/29/2025.

What is the exercise price and expiration date for the options?

The exercise price is $3.92